Description
Ticagrelor is a new type of antiplatelet agglutination drug, and it is the world's first reversible combined oral P2Y12 adenosine diphosphate receptor antagonist, which can reversibly act on the purines on vascular smooth muscle cells (VSMC) The 2 receptor (purinoceptor 2, P2) subtype P2Y12 has a significant inhibitory effect on platelet aggregation, and it takes effect quickly after oral administration, which can effectively improve the symptoms of patients with acute coronary heart disease.
